Corpus ID: 10054038

18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab.

@article{Keijsers200818FFDGPI,
  title={18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab.},
  author={Ruth G.M. Keijsers and Johan F Verzijlbergen and D.M. van Diepen and Jules M M van den Bosch and Jan C. Grutters},
  journal={Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG},
  year={2008},
  volume={25 2},
  pages={
          143-9
        }
}
BACKGROUND 18F-FDG PET is a promising technique in sarcoidosis imaging, although it is not incorporated in routine activity assessment. The purpose of this study was to correlate 18F-FDG PET with standard sarcoidosis activity parameters during infliximab treatment. METHODS Twelve patients with refractory sarcoidosis were treated with 6 cycles of infliximab. Pre- and post-therapy 18F-FDG PET was visually evaluated and SUVmax was measured. In addition, the effect of infliximab was evaluated by… Expand
Responsiveness of FDG PET/CT to Treatment of Patients With Active Chronic Sarcoidosis
TLDR
18F-FDG PET/CT is able to detect clinically meaningful changes in magnitude and extent of inflammatory activity in patients receiving treatment for active chronic sarcoidosis and is a valuable adjunct to clinical evaluation for monitoring the response to treatment in these patients. Expand
Molecular imaging in sarcoidosis
TLDR
18F-FDG PET/CT is useful in the detection of occult granuloma sites and residual activity in patients with fibrotic pulmonary sarcoidosis and has an emerging role in the therapeutic management of patients with multisystemic sarcoIDosis. Expand
The Utility of 18F-FDG PET/CT for Diagnosis and Adjustment of Therapy in Patients with Active Chronic Sarcoidosis
TLDR
It is indicated that 18F-FDG PET/CT is a useful adjunct to other diagnostic methods for detecting active inflammatory sites in chronic sarcoidosis patients with persistent symptoms, especially those with normal ACE levels. Expand
Ruolo emergente nella pratica clinica della PET con 18F-FDG nei pazienti con sarcoidosi
TLDR
Examination of the emerging role of whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with sarcoidosis shows that FDG-PET seems to be a very useful molecular imaging method for staging sarcoIDosis, identification of occult sites of involvement, guiding biopsy procedures, and monitoring patients’ responses to treatment. Expand
A predictive tool for an effective use of 18F-FDG PET in assessing activity of sarcoidosis
TLDR
The derived and internally validated clinical prediction rule, based on sIL-2R levels and HRCT scoring results, appeared to be useful to identify symptomatic sarcoidosis patients with a high probability of inflammatory activity. Expand
Follow-up of muscular sarcoidosis using fluorodeoxyglucose positron emission tomography.
TLDR
A case of symptomatic myositis revealing a recurrence of sarcoidosis with favorable outcome after initiation of infliximab is observed, which indicates that whole body fluorodeoxyglucose positron emission tomography (FDG-PET) is a useful test for both diagnosis and follow-up of myopathy in sar coidosis. Expand
Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment
TLDR
Infliximab improves PET-scan, serum markers, lung function and quality of life in patients with refractory sarcoidosis, and finds significant improvements in fatigue severity and physical functioning scores. Expand
The role of the PET scan in the management of sarcoidosis
TLDR
PET is not indicated in the standard workup, but can be of great value to complement more routinely used techniques, and offers added value in sarcoidosis patients with unexplained persistent disabling symptoms. Expand
In Which Patients with Sarcoidosis Is FDG PET/CT Indicated?
TLDR
The use of FDG PET/CT in the diagnostic process of sarcoidosis is explained, especially in determining treatable inflammatory lesions in symptomatic patients with indecisive conventional tests. Expand
Pulmonary sarcoidosis: an update
TLDR
A combined imaging modality using both FDG-PET and CT scan is more sensitive than PET alone and is now the standard of care in patients requiring biopsies of active lesions, and anti-tumor necrosis factor antibodies are being used as second line treatment in patients dependent on steroids or in cases of refractory sarcoidosis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases
TLDR
18F-FDG PET/CT allows to obtain a complete morpho-functional cartography of inflammatory active localizations and to follow treatment efficacy in patients with sarcoidosis, particularly in atypical, complex, and multisystemic forms. Expand
Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis.
TLDR
It is suggested that 18F-FDG PET can detect pulmonary lesions to a similar degree as 67Ga scintigraphy, and appears to be more accurate and contributes to a better evaluation of extrapulmonary involvement in sarcoidosis patients. Expand
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
TLDR
The results of this Phase 2 clinical study support further evaluation of anti-TNF-alpha therapy in severe, chronic, symptomatic sarcoidosis. Expand
Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis.
TLDR
Whole-bodyFDG PET scans are of value in identifying occult and reversible granulomas in patients with sarcoidosis, however, a positive FDG PET scan finding, by itself, is not an indication for treatment. Expand
Effectiveness of infliximab in treating selected patients with sarcoidosis.
TLDR
Infliximab is safe and effective in treating those patients with multisystem sarcoidosis who are either refractory or develop side effects to a standard regimen of corticosteroids and immunosuppressive agents. Expand
Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.
TLDR
A role for serum sIL-2R as marker of pulmonary disease activity and ED in patients with sarcoidosis is suggested, and there was no association between sIL -2R levels and radiographic evolution and lung function outcome. Expand
Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis.
BACKGROUND Sarcoidosis is a multiorgan inflammatory granulomatous disorder of unknown origin for which adequate markers to monitor disease severity are lacking. The aim of this study was to evaluateExpand
Serum angiotensin converting enzyme in sarcoidosis: sensitivity and specificity in diagnosis: correlations with disease activity, duration, extra-thoracic involvement, radiographic type and therapy.
TLDR
Observations indicate that SACE levels correlate well with disease activity longitudinally, both in relation to spontaneous remission and steroid therapy, and are thus helpful in patient management. Expand
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
TLDR
Infliximab is safe and efficacious in ankylosing spondylitis patients over 5 years and three types of responders were identified. Expand
Effects of sarcoid and steroids on angiotensin-converting enzyme.
TLDR
ACE levels were not useful for following disease activity in patients during a change in medication, and there was a negative correlation between changes in steroid dose and serum ACE level. Expand
...
1
2
...